Nagase (8012) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
20 Mar, 2026Executive summary
Achieved record first-quarter gross profit and improved gross profit margin across all segments, with consolidated performance exceeding full-year forecasts despite higher SG&A expenses and challenges in Prinova Group manufacturing.
Net sales rose 6.8% year-over-year to ¥239.2 billion for the quarter ended June 30, 2024, with all profit stages increasing, driven by a weaker yen and improved gross profit.
Operating income and ordinary income rose significantly year-over-year, with profit attributable to owners of the parent up 70%.
Profit attributable to owners of the parent surged 69.8% year-over-year to ¥7.4 billion, aided by reduced losses on investment securities and higher operating income.
Comprehensive income increased 44.0% year-over-year to ¥21.4 billion.
Financial highlights
Sales increased 6.8% year-over-year to ¥239.2 billion in Q1 FY2024.
Gross profit rose 18.3% to ¥45.8 billion, with a margin improvement of 1.9ppt to 19.1%.
Operating income surged 54.3% to ¥10.7 billion, with a margin of 4.5%.
Earnings per share increased to ¥65.42 from ¥37.45 a year earlier.
Shareholders’ equity ratio was 49.0%, down 0.7 points from the prior year-end.
Outlook and guidance
FY2024 guidance unchanged: sales ¥940 billion, gross profit ¥180 billion, operating income ¥36.5 billion, profit attributable to owners ¥28 billion, EPS ¥254.30.
Expect increased manufacturing earnings in semiconductor- and food-related businesses, with trading business resin sales and automobile-related business to remain firm.
SG&A expenses projected to rise with business growth, but retirement benefit actuarial differences will provide a ¥3.5 billion income in FY2024.
No changes to the previously announced earnings forecast.
Latest events from Nagase
- Record-high profits and margins in 2Q FY2024, led by strong semiconductor and materials demand.8012
Q2 202520 Mar 2026 - Record-high profits and margins from semiconductors and electronics; guidance unchanged.8012
Q3 202520 Mar 2026 - Record profits and higher dividends, with further growth forecast for the next fiscal year.8012
Q4 202520 Mar 2026 - Gross profit margin rose and full-year guidance was raised, but profit declined year-over-year.8012
Q2 202620 Mar 2026 - Record profits and a sharp net profit rise are forecast, led by semiconductors and food ingredients.8012
Q1 202620 Mar 2026 - Record-high profits and sales with strong growth in Life & Healthcare and higher dividends ahead.8012
Q3 202620 Mar 2026